Tech Company Financing Transactions

Abcuro Funding Round

Mass General Brigham Innovation, Sanofi-Genzyme BioVentures and Hongsen Investment participated in a $42 million Series A venture round for Abcuro. The round was announced on 1/8/2021.

Transaction Overview

Company Name
Abcuro
Announced On
1/8/2021
Transaction Type
Venture Equity
Amount
$42,000,000
Round
Series A
Investors

Mass General Brigham Innovation (Lead Investor) (Julius Knowles)

Sanofi-Genzyme BioVentures (Lead Investor) (Jason Hafler)

Hongsen Investment (Yajun Xu)

Pontifax Fund (Iyona Rajkomar)

RA Capital (Ryan Berry)

Samsara BioCapital (Donald McCarthy)

Proceeds Purpose
Proceeds from this financing will be used to advance ABC008, an anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy tissue in a variety of autoimmune diseases.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
90 Bridge St. 100
Newton, MA 02458
USA
Phone
(617) 714-9759
Website
www.abcuro.com
Email Address
[email protected]
Overview
We are developing first-in-class immunotherapies for autoimmune diseases and cancer through precise elimination or modulation of cytotoxic T and NK cells via KLRG1. We believe this strategy will result in therapeutics with reduced toxicity compared to existing therapeutic approaches for T cell modulation.
Profile
Abcuro LinkedIn Company Profile
Social Media
Abcuro Company Twitter Account
Company News
Abcuro News
Facebook
Abcuro on Facebook
YouTube
Abcuro on YouTube

Management Team

Title
Name
Email & Social
Chairman
Steven Greenberg
  Steven Greenberg LinkedIn Profile  Steven Greenberg Twitter Account  Steven Greenberg News  Steven Greenberg on Facebook
Chief Executive Officer
David de Graaf
  David de Graaf LinkedIn Profile  David de Graaf Twitter Account  David de Graaf News  David de Graaf on Facebook
Chief Financial Officer
David Neafus
  David Neafus LinkedIn Profile  David Neafus Twitter Account  David Neafus News  David Neafus on Facebook
Chief Medical Officer
Richard Polisson
  Richard Polisson LinkedIn Profile  Richard Polisson Twitter Account  Richard Polisson News  Richard Polisson on Facebook
Chief Operating Officer
Evan Thompson
  Evan Thompson LinkedIn Profile  Evan Thompson Twitter Account  Evan Thompson News  Evan Thompson on Facebook
Chief Scientific Officer
Stefano Gulla
  Stefano Gulla LinkedIn Profile  Stefano Gulla Twitter Account  Stefano Gulla News  Stefano Gulla on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/8/2021: Lacework venture capital transaction
Next: 1/8/2021: Voxy EnGen venture capital transaction

 

Share this article

 

About Our VC Transactions Data

Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.